Holen Sie sich die Stockscreener-App
1.66
7.61%
-0.16
Schlusskurs vom Vortag:
$1.82
Offen:
$1.8
24-Stunden-Volumen:
890.44K
Relative Volume:
0.81
Marktkapitalisierung:
$118.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-192.96M
KGV:
-0.503
EPS:
-3.3
Netto-Cashflow:
$-167.04M
1W Leistung:
+20.11%
1M Leistung:
+44.96%
6M Leistung:
-9.11%
1J Leistung:
-62.21%
1-Tages-Spanne:
$1.665
$1.84
1-Wochen-Bereich:
$1.36
$1.99
52-Wochen-Spanne:
$0.783
$5.66
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Firmenname
Ventyx Biosciences Inc
Sektor
Branche
Telefon
(858) 945-2393
Adresse
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Vergleichen Sie VTYX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
1.665 | 86.11M | 0 | -192.96M | -167.04M | -3.30 |
|
ONC
Beigene Ltd Adr
|
241.85 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.94 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
590.33 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.93 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-03-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2023-11-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-19 | Eingeleitet | Goldman | Buy |
| 2022-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-07 | Eingeleitet | Stifel | Buy |
| 2022-09-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-05-09 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-02-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-15 | Eingeleitet | Jefferies | Buy |
| 2021-11-15 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Ventyx Biosciences Inc Aktie (VTYX) Neueste Nachrichten
VTYX LAWSUIT ALERT: Levi & Korsinsky Notifies Ventyx Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Spotlight On 3 Penny Stocks With Market Caps Under $500M - simplywall.st
Price T Rowe Associates Inc. MD Sells 13,616 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Dimensional Fund Advisors LP Makes New $347,000 Investment in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Barclays PLC Boosts Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Ventyx Biosciences, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Mariner LLC Sells 8,485 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your RightsVTYX - ACCESS Newswire
Ventyx Biosciences Reports Q1 2025 Financial Results - TipRanks
Investors who lost money on Ventyx Biosciences, Inc. (VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire
Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact Levi & Korsinsky about pending Class ActionVTYX - ACCESS Newswire
Lost Money on Ventyx Biosciences, Inc.(VTYX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Shareholders of Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your RightsVTYX - ACCESS Newswire
Market Resilience: Ventyx Biosciences Inc (VTYX) Finishes Weak at 1.28, Down -5.88 - DWinneX
Ventyx Biosciences, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your RightsVTYX - ACCESS Newswire
Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ventyx Biosciences, Inc. - ACCESS Newswire
Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress - The Manila Times
Ratios Uncovered: Breaking Down Ventyx Biosciences Inc (VTYX)’s Trailing Twelve Months Metrics - DWinneX
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
VTYX SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024VTYX - ACCESS Newswire
Great week for Ventyx Biosciences, Inc. (NASDAQ:VTYX) institutional investors after losing 70% over the previous year - Yahoo Finance
Stocks of Ventyx Biosciences Inc (VTYX) are poised to climb above their peers - Sete News
Was there any good news for Ventyx Biosciences Inc (VTYX) stock in the last session? - uspostnews.com
Ventyx Biosciences Inc [VTYX] Stock sold by Insider Nuss John for $2019.0 - knoxdaily.com
VENTYX INVESTOR UPDATE: Ventyx’s (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details - ACCESS Newswire
Let’s Dive Into The Ventyx Biosciences Inc (NASDAQ: VTYX) Stock Forecast. - Marketing Sentinel
Geode Capital Management LLC Increases Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Renaissance Technologies LLC Acquires 310,800 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Stock Market Recap: Ventyx Biosciences Inc (VTYX) Concludes at 1.15, a -4.96 Surge/Decline - DWinneX
Ventyx Biosciences Inc’s Market Journey: Closing Strong at 1.43, Up 0.70 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
The Psychology of Ventyx Biosciences Inc Inc. (VTYX) Price Performance: Understanding Market Sentiment - investchronicle.com
JPMorgan Chase & Co. Trims Stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
VTYX FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class ActionVTYX - The Globe and Mail
Trading Day Review: Ventyx Biosciences Inc (VTYX) Loses Momentum, Closing at 1.16 - DWinneX
Ventyx Biosciences Inc [NASDAQ: VTYX] Sees Decrease in Stock Value - knoxdaily.com
Ventyx Biosciences Inc (VTYX) stock analysis: A comprehensive overview - uspostnews.com
Arthralgia Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis - The Globe and Mail
Is the Ventyx Biosciences Inc (NASDAQ:VTYX) stock an investment opportunity? - uspostnews.com
Ventyx Biosciences stock hits 52-week low at $0.89 amid market challenges - Investing.com Australia
Ventyx Biosciences stock hits 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
Is Ventyx Biosciences Inc (NASDAQ: VTYX) Still Trending? - stocksregister.com
Ventyx Biosciences chief scientific officer John Nuss sells $2,019 in shares - Investing.com India
VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm - ACCESS Newswire
Stock Traders Purchase Large Volume of Call Options on Ventyx Biosciences (NASDAQ:VTYX) - Defense World
Finanzdaten der Ventyx Biosciences Inc-Aktie (VTYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
17.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):